What question did this study set out to answer?

April 17, 2026Open Access

Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems

JYJunhao YangChina Pharmaceutical University HDHaixia DingNanjing Medical University

Key Points

This analysis aims to assess the cost-effectiveness of toripalimab plus bevacizumab versus sorafenib in treating advanced hepatocellular carcinoma.
Cost-effectiveness analysis comparing toripalimab plus bevacizumab and sorafenib
Evaluation based on current pricing levels
Assessment conducted within China and U.S. healthcare systems
Toripalimab plus bevacizumab is unlikely to be cost-effective compared to sorafenib
Findings apply to both China and the U.S. healthcare systems
Highlights the importance of value-based pricing strategies

Abstract

At current pricing levels, toripalimab plus bevacizumab is unlikely to be cost-effective compared with sorafenib in either China or the U.S. These findings highlight the need for value-based pricing strategies and more efficient allocation of healthcare resources.

AIに質問

Bookmark

View Full Paper